| Literature DB >> 32671964 |
L Y Wong1, N Zafari1, L Churilov1, L Stammers1, S Price1, E I Ekinci1,2, P Sumithran1,2.
Abstract
BACKGROUND: The effect of bariatric surgery on 'emotional eating' (EE) in people with obesity is unclear. This systematic review and meta-analysis aimed to examine changes in self-reported emotional eating behaviour after bariatric surgery.Entities:
Year: 2020 PMID: 32671964 PMCID: PMC7709382 DOI: 10.1002/bjs5.50318
Source DB: PubMed Journal: BJS Open ISSN: 2474-9842
Fig. 1PRISMA diagram for the review
Characteristics of studies included in the qualitative analysis
| Reference | Setting | No. of women* | Age (years)‡ | Baseline BMI (kg/m2)‡ | Procedure† |
|---|---|---|---|---|---|
| Alfonsson | Sweden (n.r.) | 101 of 129 (78·3) | 42·8(10·52) | 42·95(3·98) | RYGB (129) |
| Van der Zwaal | Netherlands (multicentre) | 14 of 14 (100) | 44·3(6) | 45·2(6·7) | RYGB (14) |
| Monpellier | Netherlands (single‐centre) | 3733 of 4569 (81·7) | 47·1(10·7) | 44·4(5·7) | RYGB (4569) |
| Pepino | USA (single‐centre) | 39 of 44 (89) | 42·8(10·8) | 47·7(8·0) | Mixed (RYGB 25, SG 8, LAGB 11) |
| Subramaniam | Malaysia (multicentre) | 37 of 57 (65) | 39·40(10·01) | 45·52(9·94) | Mixed (RYGB 30, SG 23, 1 anastomosis, gastric bypass–mini gastric bypass 4) |
| Pepino | USA (single‐centre) | 27 of 27 (100) | LAGB: 46·8(13·9)¶ | LAGB: 48·5(10·5)¶ | LAGB (10) |
| RYGB: 42·1(8·4)¶ | RYGB: 46·3(7·7)¶ | RYGB (17) | |||
| Nance | USA (single‐centre) | RYGB: 20 of 23 (87) | RYGB: 43·0(9·6) | RYGB: 46·9(7·5) | RYGB (23) |
| SG: 7 of 8 (88) | SG: 36·6(9·0) | SG: 53·3(8·7) | SG (8) | ||
| Van Hout | Netherlands (single‐centre) | 80 of 91 (88) | 38·6(8·3) | 45·7(5·1) | VBG (91) |
| Papalazarou | Greece (single‐centre) | 30 of 30 (100) | Lifestyle intervention: 32·7(6·2)¶ | Lifestyle intervention: 48·5(8·1)¶ | VBG (30) |
| Usual care group: 33·4(7·7)¶ | Usual care group: 49·8(6·2)¶ | ||||
| Holsen | USA (multicentre) | 16 of 18 (89) | 38·4(10·1) | 41·8(4·5) | SG (18) |
| Järvholm | Sweden (multicentre) | 55 of 82 (67) | 16·9(1·15) | 45·4(6·08) | RYGB (82) |
| Willmer | Sweden (multicentre) | 63 of 63 (100) | 39(5·5) | 39·2(3·3) | RYGB (63) |
| Laurenius | Sweden (n.r.) | 28 of 43 (65) | 42·6(9·7) | 44·5(4·9) | RYGB (43) |
| Turkmen | Sweden (single‐centre) | 9 of 9 (100) | 31·4(7·41) | 47·2(8·85) | RYGB (9) |
| Søvik | Norway and Sweden (multicentre) | RYGB: 23 of 31 (74) | RYGB: 35·2(7·0) | RYGB: 54·8(3·24) | RYGB (31) |
| DS: 19 of 29 (66) | DS: 36·1(5·26) | DS: 55·2(3·49) | DS (29) | ||
| Bryant | UK (n.r.) | 9 of 12 (75) | 36(2) | 45·3(1·9) | RYGB (12) |
| Petereit | Lithuania (single‐centre) | 128 of 180 (71·1) | 42·7(10·5) | 45·2(6·4) | RYGB (180) |
| Woodard | USA (single‐centre) | 28 of 35 (80) | 48(11)¶ | 48·7(8·3)¶ | RYGB (35) |
| Nasirzadeh | Canada (multicentre) | 658 of 844# (81·2) | 45 (38–53)§ | 48·6(7·8) | Mixed (RYGB 760, SG 84) |
| Castellini | Italy (single‐centre) | LAGB: 23 of 27 (85) | LAGB: 43·85(11·36) | LAGB: 44·79(5·3) | LAGB (27) |
| RYGB: 28 of 30 (93) | RYGB: 43·63(9·83) | RYGB: 49·49(6·76) | RYGB (30) | ||
| BPD: 24 of 26 (92) | BPD: 48·84(8·36) | BPD: 50·57(6·55) | BPD (26) | ||
| Dymek | USA (single‐centre) | 26 of 32 (81) | 39·1(8·47) | 56·7(11·5) | RYGB (32) |
| Weineland | Sweden (single‐centre) | 171 of 186 (91·9) | 42·2(9·3) | 36·2(3·6) | Mixed (SG 130, RYGB 56) |
| Sioka | Greece (single‐centre) | < 3 months: 7 of 10 (70) | < 3 months: 38·2(10·76) | < 3 months: 43·68(8·29) | SG (110) |
| 3–6 months: 11 of 11 (100) | 3–6 months: 38(9·96) | 3–6 months: 43·85(5·69) | |||
| 6–12 months: 7 of 11 (64) | 6–12 months: 42·1(10·9) | 6–12 months: 45·85(6·13) | |||
| 1–2 years: 31 of 39 (79) | 1–2 years: 39·56(9·15) | 1–2 years: 46·05(5·83) | |||
| 2–3 years: 19 of 23 (83) | 2–3 years: 40·39(9·68) | 2–3 years: 46·52(6·81) | |||
| > 3 years: 11 of 16 (69) | > 3 years 38·63(10·83) | > 3 years: 44·81(5·63) |
Values in parentheses are *percentages and †number of patients. ‡Values are mean(s.d.) unless indicated otherwise; §values are mean (i.q.r.). ¶Data converted from originally reported outcome data into mean(s.d.) values using Review Manager 5.3. #Of a total 844 participants, only 810 had their sex recorded (658 women and 152 men). n.r., Not reported; RYGB, Roux‐en‐Y gastric bypass; SG, sleeve gastrectomy; LAGB, laparoscopic adjustable gastric band; VBG, vertical banded gastroplasty; DS, duodenal switch; BPD, biliopancreatic diversion.
Emotional eating outcomes of studies included in the qualitative analysis
| Change from preop. baseline/control§ | Trends after surgery§ | |||||||
|---|---|---|---|---|---|---|---|---|
| Reference | Questionnaire | Assessment time points (months) | Outcome* | MD |
| MD |
| No. analysed of total enrolled (retention rate)# |
| 34 | GFCQ‐T | Preop. | 2·27(1·03) | n.a. | n.a. | 129 of 177 (72·9) | ||
| 1 | 1·39(0·72) | −0·88 (−1·10, −0·66)** | < 0·001 | n.a. | 129 of 177 (72·9) | |||
| 35 | DEBQ and GFCQ‐T | Preop. | DEBQ: 2·53(0·86) | n.a. | n.a. | 14 of 20 (70) | ||
| GFCQ‐T: 2·97(1·37) | ||||||||
| > 24 | DEBQ: 2·10(0·72) | DEBQ: −0·43 (−1·05, 0·19)** | 0·034 | n.a. | 14 of 20 (70) | |||
| GFCQ‐T: 2·14(0·80) | GFCQ‐T: −0·83 (−1·71, 0·05)** | 0·035 | ||||||
| 24 | DEBQ | Preop. | 2·43(0·82) | n.a. | n.a. | 2028 of 4829 (42·0) | ||
| 15 | 1·94(0·77) | −0·49 (−0·54, −0·44)** | ≤ 0·001 | n.a. | 1939 of 4829 (40·2) | |||
| 24 | 2·09(0·78) | −0·34 (−0·39, −0·29)** | 15 | ≤ 0·001 | 1401 of 4829 (29·0) | |||
| 36 | 2·27(0·82) | −0·16 (−0·25, −0·07)** | 24 | > 0·05 | 388 of 4829 (8·0) | |||
| 48 | 2·35(0·86) | −0·08 (−0·24, 0·08)** | 36 | > 0·05 | 112 of 4829 (2·3) | |||
| 36 | DEBQ | Preop. | 2·73(0·97)†† | n.a. | n.a. | 44 of 51 (86) | ||
| After about 20% (range 15–28%) surgery‐induced weight loss (within 9 months) | 1·95(0·80)†† | −0·78 (−1·15, −0·41)** | < 0·001 | n.a. | 44 of 51 (86) | |||
| 32 | DEBQ | Preop. | 2·06(0·94) | n.a. | n.a. | 57 of 80 (71) | ||
| 3 | 1·64(0·80) | −0·42 (−0·78, −0·06)** | n.a. | 45 of 80 (56) | ||||
| 6 | 1·81(0·81) | −0·25 (−0·63, 0·13)** | 3 | 36 of 80 (45) | ||||
| 38 | DEBQ | Preop. | RYGB: 2·8(0·8) | n.a. | n.a. | RYGB: 17 of 17 (100)†† | ||
| LAGB: 3·2(1·0) | LAGB: 10 of 10 (100) | |||||||
| After about 20% surgery‐induced weight loss (within 9 months) | RYGB: 1·9(0·7) | RYGB: −0·90 (−1·41, −0·39)** | n.a. | RYGB: 17 of 17 (100) | ||||
| LAGB: 2·3(1·0) | LAGB: −0·90 (−1·78, −0·023)** | < 0·001 | LAGB: 10 of 10 (100) | |||||
| 4 | DEBQ | Preop. | SG: 2·8(0·9) | n.a. | n.a. | SG: 8 of 8 (100) | ||
| RYGB: 2·6(0·9) | RYGB: 23 of 23 (100) | |||||||
| After about 20% surgery‐induced weight loss | SG: 2·2(0·6) | SG: −0·6 (−1·04, −0·16)** | n.a. | SG: 8 of 8 (100) | ||||
| RYGB: 1·8(0·7) | RYGB: −0·80 (−1·66, 0·07)** | RYGB: 23 of 23 (100) | ||||||
| 37 | DEBQ | Preop. | 2·4(0·8) | n.a. | n.a. | 81 of 91 (89) | ||
| 6 | 1·9(0·8) | −0·50 (−0·75, −0·25)** | ≤ 0·01 | n.a. | 81 of 91 (89) | |||
| 12 | 2·0(0·8) | −0·40 (−0·65, −0·15)** | ≤ 0·01 | 6 | > 0·05 | 81 of 91 (89) | ||
| 24 | 2·2(0·9) | −0·20 (−0·46, 0·06)** | > 0·05 | 12 | > 0·05 | 81 of 91 (89) | ||
| 43 | DEBQ | Preop. | Usual care: 3·2(0·77)** | n.a. | n.a. | Usual care: 15 of 15 (100) | ||
| Lifestyle: 3·6(0·77)** | Lifestyle: 15 of 15 (100) | |||||||
| 3 | Usual care: 2·6(0·39)** | −0·60 (−1·0, −0·16)** | n.a. | Usual care: 15 of 15 (100) | ||||
| Lifestyle: 2·6(0·39)** | −1·00 (−1·44, −0·56)** | Lifestyle: 15 of 15 (100) | ||||||
| 12 | Usual care: 2·5(0·77)** | −0·70 (−1·13, −0·15)** | 3 | Usual care: 15 of 15 (100) | ||||
| Lifestyle: 2·5(0·39)** | −1·10 (−1·54, −0·66)** | 3 | Lifestyle: 15 of 15 (100) | |||||
| 36 | Usual care: 3·2(0·39)** | −0·00 (−0·44, 0·44)** | 12 | Usual care: 15 of 15 (100) | ||||
| Lifestyle: 3·1(0·39)** | −0·50 (−0·94, −0·06)** | 12 | Lifestyle: 15 of 15 (100) | |||||
| 40 | DEBQ and TFEQ‐R21 | Preop. | DEBQ: 3·2(0·7) | n.a. | n.a. | 18 of 20 (90) | ||
| TFEQ‐R21: 60·2(24·8) | ||||||||
| 12 | DEBQ: 1·9(0·9) | DEBQ: −1·30 (−1·83, −0·77)** | < 0·001 | n.a. | 18 of 20 (90) | |||
| TFEQ‐R21: 27·5(22·4) | TFEQ‐R21: −32·70 (−44·16, ‐21·24)** | < 0·001 | ||||||
| 41 | TFEQ‐R21 | Preop. | Mixed model: 40·6 (35·4, 45·8)† | n.a. | n.a. | 81 of 82 (99) | ||
| 12 | Mixed model: 20·8 (15·7, 25·8)† | Mixed model: −19·9 (−27·7, −12·0)† | n.a. | 81 of 82 (99) | ||||
| 24 | Mixed model: 24·9 (19·6, 30·2)† | Mixed model: −15·7 (−24·2, −7·3)† | 12 | 73 of 82 (89) | ||||
| 33 | TFEQ‐R21 | Preop. | 15·2(n.r.) | n.a. | n.a. | 52 of 63 (83) | ||
| 9 | 9·9(n.r.) | −5·31 (−6·66, −3·96) | ≤ 0·001 | n.a. | 52 of 63 (83) | |||
| 31 | TFEQ‐R21 | Preop. | 53·7 (46·8, 60·7)†‡‡ | n.a. | n.a. | 43 of 47 (91) | ||
| 6 weeks | 27·4 (20·4, 34·5)†‡‡ | −26·3 (−36·9, −15·6)** | < 0·001 | n.a. | RYGB: 42 of 47 (89) | |||
| 12 | 27·1 (19·3, 34·8)†‡‡ | −26·6 (−36·6, −16·6)** | < 0·001 | 6 weeks | RYGB: 27 of 47 (57) | |||
| 24 | 38·8 (29·8, 47·9)†‡‡ | −14·90 (−21·99, −7·81)** | 0·046 | 12 | RYGB: 34 of 47 (72) | |||
| 29 | TFEQ‐R21 | Preop. | 47·90(27·56) | n.a. | n.a. | 9 of 9 (100)** | ||
| 6 | 32·06(27·46) | −15·84 (−42·0, 10·36)** | n.a. | 8 of 9 (89)§§ | ||||
| 12 | 33·76 (23·96) | −14·14 (−38·63, 10·35)** | 6 | 8 of 9 (89)§§ | ||||
| 42 | TFEQ‐R21 | Preop. | RYGB: 44·4 (34·1, 54·8)†¶¶ | n.a. | n.a. | RYGB: 31 of 31 (100) | ||
| DS: 50·0 (39·8, 60·2)†¶¶ | DS: 29 of 29 (100) | |||||||
| 12 | RYGB: 36·4 (26·1, 46·8)†¶¶ | RYGB: −8·00 (−22·04, 6·04)** | < 0·05 | n.a. | RYGB: 31 of 31 (100) | |||
| DS: 28·8 (18·1, 39·5)†¶¶ | DS: −21·20 (−35·34, −7·06)** | < 0·05 | DS: 29 of 29 (100) | |||||
| 24 | RYGB: 35·1 (25·2, 45·0)†¶¶ | RYGB: −9·30 (−23·04, 4·44)** | < 0·05 | 12 | 0·853 | RYGB: 31 of 31 (100)## | ||
| DS: 32·5 (22·2, 42·9)†¶¶ | DS: −17·5 (−31·4, −3·6)** | < 0·05 | 12 | DS: 29 of 29 (100)## | ||||
| 23 | TFEQ‐R18 | Preop. | 58·89 (33·15) | n.a. | n.a. | 12 of 14 (86) | ||
| 3 days | 61·11 (31·25) | 2·22 (−25·06, 29·50)** | > 0·05 | n.a. | 12 of 14 (86) | |||
| 2 | 37·04 (24·77) | −21·85 (−46·63, 2·93)** | > 0·05 | 3 days | 12 of 14 (86) | |||
| 12 | 37·37 (24·48) | −21·52 (−46·19, 3·152)** | > 0·05 | 2 | 12 of 14 (86) | |||
| 25 | TFEQ‐R18 | Preop. | 28·2(n.r.) | n.a. | n.a. | 180 of 180 (100)‡‡ | ||
| 12 | 17·2(n.r.) | < 0·001 | n.a. | 180 of 180 (100)‡‡ | ||||
| 27 | TFEQ‐R18 | Preop. | 56(6)‡ | n.a. | n.a. | 35 of 35 (100)‡‡ | ||
| 12 | 25(5)‡ | −51·0 (−66·3, −35·7)** | < 0·001 | n.a. | 35 of 35 (100)‡‡ | |||
| 26 | EES | Preop. | n.r. | n.a. | n.a. | 698 of 844 (82·7) | ||
| 12 | n.r. | Preop. | < 0·01 | n.a. | 549 of 844 (65·0) | |||
| 24 | n.r. | Preop. | < 0·01 | 12 | < 0·05 | 382 of 844 (45·3) | ||
| 36 | n.r. | Preop. | < 0·01 | 12 | < 0·01 | 240 of 844 (28·4) | ||
| 24 | > 0·05 | |||||||
| 28 | EES | Preop. | LAGB: 46·25(9·88) | n.a. | n.a. | LAGB: 27 of 30 (90) | ||
| RYGB: 43·14(12·43) | RYGB: 30 of 31 (97) | |||||||
| BPD: 46·76(10·01) | BPD: 26 of 30 (87) | |||||||
| 12 | LAGB: 1·30(1·03) | LAGB: −44·95 (−48·70, −41·20)** | n.a. | LAGB: 27 of 30 (90) | ||||
| RYGB: 0·75(0·73) | RYGB: −42·39 (−46·85, −37·93)** | RYGB: 30 of 31 (97) | ||||||
| BPD: 0·79(0·51) | BPD: −45·97 (−49·82, −42·12)** | BPD: 26 of 30 (87) | ||||||
| 39 | EES | Preop. | EES anger subscale: 13·9(10·3) | n.a. | n.a. | 32 of 32 (100) | ||
| EES anxiety subscale: 11·3(8·0) | ||||||||
| EES depression subscale: 8·9(5·3) | ||||||||
| 2 weeks | EES anger subscale: 5·3(8·4) | EES anger subscale: −8·60 (−13·2, −4·00)** | n.a. | 32 of 32 (100) | ||||
| EES anxiety subscale: 4·7(7·3) | EES anxiety subscale: −6·60 (−10·35, −2·85)** | |||||||
| EES depression subscale: 3·8(5·3) | EES depression subscale: −5·10 (−7·70, −2·50)** | |||||||
| 6 | EES anger subscale: 5·1(9·5) | EES anger subscale: −8·80 (−14·3, −3·31)** | EES anger subscale, 2 weeks | 20 of 32 (63) | ||||
| EES anxiety subscale: 5·4(7·8) | EES anxiety subscale: −5·9 (−1·5, −10·3)** | EES anxiety subscale, 2 weeks | ||||||
| EES depression subscale: 2·5(4·2) | EES depression subscale: −6·40 (−9·00, −3·80)** | EES depression subscale, 2 weeks | ||||||
| 30 | EOQ | Preop. | 1·28(1·05) | n.a. | n.a. | 32 of 186 (17·2) | ||
| 6 | 0·83(0·88) | −0·45 (−0·92, 0·03)** | n.a. | 32 of 186 (17·2) | ||||
| 22 | Interview assessment by dietician††† | Preop. | < 3 months: 0% | n.a. | n.a. | < 3 months: 10*** | ||
| 3–6 months: 46·8%¶¶ | 3–6 months: 11*** | |||||||
| 6–12 months: 19·5%¶¶ | 6–12 months: 11*** | |||||||
| 1–2 years: 9·0%¶¶ | 1–2 years: 39*** | |||||||
| 2–3 years: 14·5%¶¶ | 2–3 years: 23*** | |||||||
| > 3 years: 6·0%¶¶ | > 3 years: 16*** | |||||||
| Postop. | < 3 months: 10%¶¶ | n.r. | n.a. | < 3 months: 10*** | ||||
| 3–6 months: 0%¶¶ | 3–6 months: 11*** | |||||||
| 6–12 months: 0%¶¶ | 6–12 months: 11*** | |||||||
| 1–2 years: 2·5%¶¶ | 1–2 years: 39*** | |||||||
| 2–3 years: 0%¶¶ | 2–3 years: 23*** | |||||||
| > 3 years: 12·4%¶¶ | > 3 years: 16*** | |||||||
*Values are mean(s.d.) unless indicated otherwise; values are †mean (95 per cent c.i.) and ‡mean(s.e.). §Values are mean difference (MD) (95 per cent c.i.) unless indicated otherwise; ¶values are mean (95 per cent c.i.). #Values in parentheses are percentages. **Data converted using Review Manager 5.3 from originally reported outcome data into standard deviation, MD and/or 95 per cent confidence intervals. ††Data received through personal email communication with author. ‡‡For purposes of analysis, retention rate assumed to be 100 per cent as the number of people excluded or loss to follow‐up was not reported explicitly; retention rate may be overestimated. §§Ambiguous interpretation of data from study; number of analysed participants may be either eight or nine. ¶¶Results converted electronically from a graphical to numerical format using PlotDigitizer. ##Two participants were lost to follow‐up at 24 months, but it was not mentioned which groups this occurred in, or numbers used for analysis. ***Study had a total of 23 dropouts/exclusions, but did not state in which groups these dropouts occurred; these patients were excluded from analysis. †††Interview assessment by dietician according to International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) European Accreditation Council for Bariatric Surgery (proportion classified as ‘emotional eaters’). GFCQ‐T, General Food Craving Questionnaire – Trait; n.a., not applicable; DEBQ, Dutch Eating Behaviour Questionnaire; RYGB, Roux‐en‐Y gastric bypass; LAGB, laparoscopic adjustable gastric band; SG, sleeve gastrectomy; TFEQ‐R21/R18, Three‐Factor Eating Questionnaire – Revised 21/18; n.r., not reported; DS, duodenal switch; EES, Emotional Eating Scale; BPD, biliopancreatic diversion; EOQ, Emotional Overeating Questionnaire.
Quality assessment of included studies according to the National Heart, Lung, and Blood Institute quality assessment tool for before–after (pre–post) studies with no control group
| Reference | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Quality rating (of 11) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | Y | N | Y | ? | ? | N | Y | ? | N | Y | N | n.a. | Poor (4) |
| 23 | Y | N | N | ? | ? | Y | Y | ? | Y | Y | N | n.a. | Poor (5) |
| 28 | N | Y | Y | N | ? | Y | Y | ? | Y | Y | N | n.a. | Good (6) |
| 39 | Y | N | N | ? | ? | Y | Y | ? | N | Y | N | n.a. | Fair (4) |
| 40 | Y | Y | N | ? | ? | N | Y | ? | Y | Y | N | n.a. | Good (5) |
| 41 | Y | Y | N | N | ? | Y | Y | ? | Y | Y | N | n.a. | Good (6) |
| 31 | Y | N | N | ? | ? | Y | Y | ? | Y | Y | N | n.a. | Fair (5) |
| 24 | Y | N | ? | N | ? | N | Y | ? | N | Y | N | n.a. | Poor (3) |
| 4 | Y | N | N | ? | Y | Y | Y | ? | Y | Y | N | n.a. | Fair (6) |
| 26 | Y | Y | Y | Y | ? | N | Y | ? | N | Y | N | n.a. | Fair (6) |
| 43 | Y | Y | N | ? | ? | N | Y | ? | ? | Y | N | n.a. | Fair (4) |
| 36 | Y | N | N | ? | ? | Y | Y | ? | Y | Y | N | n.a. | Fair (5) |
| 38 | Y | N | N | ? | ? | Y | Y | ? | ? | Y | N | n.a. | Fair (4) |
| 25 | Y | Y | Y | N | ? | Y | Y | ? | N | Y | N | n.a. | Fair (6) |
| 22 | Y | Y | Y | Y | ? | Y | N | ? | Y | N | N | n.a. | Poor (6) |
| 42 | Y | Y | N | ? | Y | Y | Y | N | Y | Y | N | n.a. | Fair (7) |
| 32 | N | N | Y | ? | ? | N | Y | ? | N | Y | N | n.a. | Fair (3) |
| 29 | Y | N | N | Y | ? | Y | Y | ? | Y | Y | N | n.a. | Fair (6) |
| 35 | Y | N | N | ? | ? | N | Y | ? | Y | Y | N | n.a. | Poor (4) |
| 37 | Y | Y | Y | N | ? | Y | Y | ? | Y | Y | N | n.a. | Good (7) |
| 30 | Y | N | Y | Y | ? | N | Y | ? | N | N | N | n.a. | Poor (4) |
| 33 | Y | Y | N | ? | ? | N | Y | ? | Y | Y | N | n.a. | Fair (5) |
| 27 | N | N | N | ? | ? | N | Y | ? | Y | Y | N | n.a. | Fair (3) |
| Total (of 23) | 20 | 10 | 8 | 4 | 2 | 13 | 22 | 0 | 14 | 21 | 0 | n.a. |
1. Was the study question or objective clearly stated?
2. Were eligibility/selection criteria for the study population prespecified and described clearly?
3. Were the participants in the study representative of those who would be eligible for the test/service/intervention in the general or clinical population of interest?
4. Were all eligible participants that met the prespecified entry criteria enrolled?
5. Was the sample size sufficiently large to provide confidence in the findings?
6. Was the test/service/intervention clearly described and delivered consistently across the study population?
7. Were the outcome measures prespecified, clearly defined, valid, reliable, and assessed consistently across all study participants?
8. Were the people assessing the outcomes blinded to the participants' exposures/interventions?
9. Was the loss to follow‐up after baseline 20 per cent or less? Were those lost to follow‐up accounted for in the analysis?
10. Did the statistical methods examine changes in outcome measures from before to after the intervention? Were statistical tests done that provided P values for the pre‐to‐post changes?
11. Were outcome measures of interest taken multiple times before the intervention and multiple times after the intervention (did they use an interrupted time‐series design)?
12. If the intervention was conducted at a group level (such as a whole hospital or community), did the statistical analysis take into account the use of individual‐level data to determine effects at the group level?
Y, yes; N, no; ?, not reported or cannot be determined; n.a., not applicable.
Fig. 2Forest plot of the effect of bariatric surgery on emotional eating Values are mean(s.d.). An inverse‐variance random‐effects model was used for meta‐analysis. Standardized mean differences (SMDs) are shown with 95 per cent confidence intervals.
Effect of sensitivity analysis on meta‐analysis
| Total no. of patients | |||||
|---|---|---|---|---|---|
| Outcome of interest | No. of studies |
|
| SMD |
|
|
| |||||
| Removal of studies with only age ≤ 18 years | 16 | 2730 | 2592 | 1·11 (0·76, 1·47) | 94 |
|
| |||||
| Removal of women‐only studies | 14 | 2745 | 2608 | 1·10 (0·73, 1·46) | 94 |
|
| |||||
| Good quality studies only | 3 | 263 | 263 | 2·12 (0·34, 3·90) | 98 |
| Good and fair quality studies only | 13 | 599 | 561 | 1·24 (0·69, 1·80) | 94 |
|
| |||||
| TFEQ‐R18 | 2 | 58 | 47 | 0·86 (0·45, 1·27) | n.a. |
| TFEQ‐R21 | 5 | 211 | 194 | 0·85 (0·54, 1·16) | 47 |
| DEBQ | 8 | 2316 | 2206 | 0·81 (0·57, 1·04) | 68 |
| EES | 1 | 83 | 83 | 5·71 (5·02, 6·40) | n.a. |
| EOQ | 1 | 32 | 32 | 0·46 (−0·04, 0·96) | n.a. |
| GFCQ‐T | 1 | 129 | 129 | 0·99 (0·73, 1·25) | n.a. |
|
| |||||
| Alfonsson | 16 | 2682 | 2544 | 1·10 (0·74, 1·47) | 94 |
| Bryant | 16 | 2788 | 2661 | 1·11 (0·77, 1·46) | 94 |
| Castellini | 16 | 2728 | 2590 | 0·79 (0·64, 0·94) | 59 |
| Holsen | 16 | 2793 | 2655 | 1·06 (0·72, 1·40) | 94 |
| Järvholm | 16 | 2730 | 2592 | 1·11 (0·76, 1·47) | 94 |
| Laurenius | 16 | 2768 | 2646 | 1·08 (0·74, 1·43) | 94 |
| Monpellier | 16 | 783 | 734 | 1·14 (0·70, 1·57) | 93 |
| Nance | 16 | 2780 | 2642 | 1·10 (0·75, 1·45) | 94 |
| Papalazarou | 16 | 2781 | 2643 | 1·08 (0·74, 1·42) | 94 |
| Pepino | 16 | 2767 | 2629 | 1·11 (0·76, 1·46) | 94 |
| Pepino | 16 | 2784 | 2646 | 1·08 (0·73, 1·42) | 94 |
| Subramaniam | 16 | 2754 | 2637 | 1·14 (0·80, 1·49) | 94 |
| Søvik | 16 | 2751 | 2613 | 1·13 (0·78, 1·49) | 94 |
| Turkmen | 16 | 2802 | 2665 | 1·12 (0·78, 1·46) | 94 |
| van Hout | 16 | 2730 | 2592 | 1·13 (0·77, 1·49) | 94 |
| Weineland | 16 | 2779 | 2641 | 1·13 (0·78, 1·48) | 94 |
| Woodard | 16 | 2776 | 2638 | 1·10 (0·75, 1·45) | 94 |
|
| |||||
| Removal of all studies where mean(3 s.d.) included negative values | 1 | 30 | 30 | 1·26 (0·70, 1·81) | n.a. |
Values in parentheses are 95 per cent confidence intervals. SMD, standardized mean difference; TFEQ‐R18/21, Three‐Factor Eating Questionnaire – Revised 18/21; n.a. not applicable; DEBQ, Dutch Eating Behaviour Questionnaire; EES, Emotional Eating Scale; EOQ, Emotional Overeating Questionnaire; GFCQ‐T, General Food Craving Questionnaire – Trait.
Fig. 3Forest plot of the effect of different types of bariatric surgery on emotional eating in studies using revised versions of the Three‐Factor Eating Questionnaire: standardized mean differences Values are mean(s.d.). An inverse‐variance random‐effects model was used for meta‐analysis. Standardized mean differences (SMDs) are shown with 95 per cent confidence intervals. RYGB, Roux‐en‐
Fig. 4Forest plot of the effect of different types of bariatric surgery on emotional eating in studies using revised versions of the Three‐Factor Eating Questionnaire: mean differences Values are mean(s.d.). An inverse‐variance random‐effects model was used for meta‐analysis. Mean differences (MDs) are shown with 95 per cent confidence intervals. RYGB, Roux‐en‐
Fig. 5Forest plot of the effect of different types of bariatric surgery on emotional eating in studies using the Dutch Eating Behaviour Questionnaire: standardized mean differences Values are mean(s.d.). An inverse‐variance random‐effects model was used for meta‐analysis. Standardized mean differences (SMDs) are shown with 95 per cent confidence intervals. RYGB, Roux‐en‐
Fig. 6Forest plot of the effect of different types of bariatric surgery on emotional eating in studies using the Dutch Eating Behaviour Questionnaire: mean differences Values are mean(s.d.). An inverse‐variance random‐effects model was used for meta‐analysis. Mean differences (MDs) are shown with 95 per cent confidence intervals. RYGB, Roux‐en‐
Fig. 7Funnel plot with pseudo 95 per cent confidence limits SMD, standardized mean difference.